Literature DB >> 11307624

Increased microglia proliferation separates pilocytic astrocytomas from diffuse astrocytomas: a double labeling study.

R Klein1, W Roggendorf.   

Abstract

It is not known how many non-tumorous cells in gliomas contribute to the proliferation rate. We investigated the proliferative activity of microglia in an immunohistochemical double-labeling study of pilocytic astrocytomas and astrocytomas WHO grade II-IV using the antibodies MIB-1 (Ki67) as proliferation-marker and Ki-M1P (CD68) as microglia marker. We found the highest indices of proliferating microglia in pilocytic astrocytomas with an average rate of 32% (+/- 6.8) of all proliferating cells. In contrast, the proliferation indices of microglia were lowest in fibrillary astrocytomas with 8.6% (+/- 2.5) of all proliferating cells. In anaplastic astrocytomas and glioblastomas the percentage of proliferating microglia showed a slight increase to 8.8% (+/- 3.6) and 13.4% (+/- 8.7), respectively. We conclude that microglial cells in astrocytic brain tumors proliferate and show different proliferative activities at different grades of malignancy with the highest rates of proliferating microglia especially in pilocytic astrocytomas. Thus, the proliferation rate does not solely reflect the proliferation of tumor cells, but also of non-tumorous cells. This should be considered in particular when proliferation rates are used as a criterion for prognosis and grading of pilocytic astrocytomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11307624     DOI: 10.1007/s004010000286

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  17 in total

1.  Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors.

Authors:  Maroulio Talieri; Marita Zoma; Marina Devetzi; Andreas Scorilas; Alexandros Ardavanis
Journal:  Tumour Biol       Date:  2012-04-03

2.  Increased β-catenin/Tcf signaling in pilocytic astrocytomas: a comparative study to distinguish pilocytic astrocytomas from low-grade diffuse astrocytomas.

Authors:  Gangadhara Reddy Sareddy; Khamushavalli Geeviman; Manas Panigrahi; Sundaram Challa; Anita Mahadevan; Phanithi Prakash Babu
Journal:  Neurochem Res       Date:  2011-09-16       Impact factor: 3.996

Review 3.  The role of microglia and macrophages in glioma maintenance and progression.

Authors:  Dolores Hambardzumyan; David H Gutmann; Helmut Kettenmann
Journal:  Nat Neurosci       Date:  2016-01       Impact factor: 24.884

4.  Microglia/macrophages promote glioma progression.

Authors:  Haiyan Zhai; Frank L Heppner; Stella E Tsirka
Journal:  Glia       Date:  2010-12-29       Impact factor: 7.452

5.  Pilocytic astrocytoma demethylation and transcriptional landscapes link bZIP transcription factors to immune response.

Authors:  Christian F Aichmüller; Murat Iskar; David T W Jones; Andrey Korshunov; Bernhard Radlwimmer; Marcel Kool; Aurelie Ernst; Stefan M Pfister; Peter Lichter; Marc Zapatka
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

6.  Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.

Authors:  Grant W Simmons; Winnie W Pong; Ryan J Emnett; Crystal R White; Scott M Gianino; Fausto J Rodriguez; David H Gutmann
Journal:  J Neuropathol Exp Neurol       Date:  2011-01       Impact factor: 3.685

7.  The gut microbiome regulates the increases in depressive-type behaviors and in inflammatory processes in the ventral hippocampus of stress vulnerable rats.

Authors:  Jiah Pearson-Leary; Chunyu Zhao; Kyle Bittinger; Darrell Eacret; Sandra Luz; Abigail S Vigderman; Gabriel Dayanim; Seema Bhatnagar
Journal:  Mol Psychiatry       Date:  2019-03-04       Impact factor: 15.992

8.  PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status.

Authors:  Allison M Martin; W Robert Bell; Ming Yuan; Lauren Harris; Bradley Poore; Antje Arnold; Elizabeth L Engle; Laura Asnaghi; Michael Lim; Eric H Raabe; Charles G Eberhart
Journal:  J Neuropathol Exp Neurol       Date:  2020-01-01       Impact factor: 3.148

Review 9.  Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ Regimen.

Authors:  Michael E Salacz; Richard E Kast; Najmaldin Saki; Ansgar Brüning; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Onco Targets Ther       Date:  2016-04-27       Impact factor: 4.147

10.  Tumor microenvironment in the brain.

Authors:  Mihaela Lorger
Journal:  Cancers (Basel)       Date:  2012-02-22       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.